PPIDT00232
Drug Information
| Name | Degarelix |
|---|---|
| Sequence | Not Available |
| DrugBank_ID | DB06699 |
| Type | small molecule |
| Indication | In Canada and the US, degarelix is indicated for the treatment of advanced prostate cancer in patients requiring androgen deprivation therapy.[L49355,L49360] In the EU, it is more specifically indicated for the treatment of adult male patients with advanced hormone-dependent prostate cancer, and for treatment of high-risk localized and locally advanced hormone-dependent prostate cancer, in combination with radiotherapy or as a neo-adjuvant prior to radiotherapy.[L49374] |
Dosage Forms
| Form | Route | Strength |
|---|---|---|
| Injection, powder, for solution | Parenteral; Subcutaneous |
120 MG
|
| Injection, powder, for solution | Parenteral; Subcutaneous |
80 MG
|
| Injection, powder, lyophilized, for solution; kit | Subcutaneous |
20 mg/1mL
|
| Injection, powder, lyophilized, for solution; kit | Subcutaneous |
40 mg/1mL
|
| Powder, for solution | Subcutaneous |
120 mg / vial
|
| Powder, for solution | Subcutaneous |
80 mg / vial
|
| Powder, metered | Subcutaneous |
20 mg/1mL
|
| Powder, metered | Subcutaneous |
40 mg/1mL
|
| Injection, powder, lyophilized, for solution | Subcutaneous |
12000000 mg
|
| Injection, powder, lyophilized, for solution | Subcutaneous |
8000000 mg
|
| Powder | Subcutaneous |
|
| Solution | Subcutaneous |
88.200 mg
|
| Injection, powder, for solution | Subcutaneous |
120 mg
|
| Injection, powder, for solution | Subcutaneous |
80 mg
|
| Powder | Subcutaneous |
120 mg/1vial
|
| Powder | Subcutaneous |
80 mg/1vial
|